Effect of Maa-al-shaeer (An Iranian Traditional Medicine product) on treatment of allergic rhinitis
Phase 2
- Conditions
- Allergic Rhinitis.Allergic rhinitis, unspecified
- Registration Number
- IRCT2015082323732N1
- Lead Sponsor
- Vice chancellor for research, Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
All patients 7 years to 65 years old that according to the ARIA guideline and diagnosis of a pulmonologist have allergic rhinitis a
Exclusion criteria: Diffused Nasal Polyps; Pregnancy; history of allergy to Fexofenadine or barley; Celiac disease; systemic inflammatory diseases; using antihistamines during the last week before the beginning of the study; using Corticosteroids during the last 2 weeks before the beginning of the study; Using other antihistamine drugs during the study; using corticosteroid drugs during the study; Lack of consent from the patient to stay in the study for any reason; drug intolerance or allergic reactions
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical symptoms. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: JTFPP questionnaire and based on VAS.;IFN-gamma. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: Blood sample and measurement using RT-PCR.;IL-4. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: Blood sample and measurement using RT-PCR.;IL-17. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: Blood sample and measurement using RT-PCR.;TGF-beta. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: Blood sample and measurement using RT-PCR.;Ig-E levels. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: Blood sample / IU/ml.;Blood Eosinophil level. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: Blood sample / IU/ml.;Nasal smear eosinophil count. Timepoint: Baseline and 2 weeks after intervention. Method of measurement: eosinophil count in nasal smear.
- Secondary Outcome Measures
Name Time Method Symptom recurrence rate. Timepoint: Baseline and one week after the end of intervention. Method of measurement: RCAT questionnaire.;Levels of AST, ALT, BUN, Cr in the group taking the Ma-al-Shaeer to evaluate its effect on hepatic and renal function. Timepoint: Baseline and two weeks after intervention. Method of measurement: blood samples.